Bengaluru, India, February 11, 2025: Everest Group, a leading global research and consulting firm, has recognized Indegene as a front-runner in generative AI (GenAI) life sciences market adoption. In its report, ‘AI-deas to Action: Operationalizing Generative AI in Life Sciences’, Everest Group acknowledged Indegene’s comprehensive GenAI capabilities, including scale, breadth of use cases, strategic partnerships and value delivered to clients.
The report highlights how Indegene’s holistic GenAI strategy and enterprise-grade, production-ready solutions are helping life sciences companies streamline operations and realize strong productivity improvements across several use cases, spanning the clinical, medical and commercial elements of the life sciences value chain.
“We believe GenAI is a generational opportunity for life sciences leaders to make the strategic leap and drive transformational business impact. And we are helping them make the most of GenAI’s potential – solve real business challenges, prioritize use cases that deliver clear business outcomes, and realize benefits in a responsible and compliant way”, said Tarun Mathur, CTO, Indegene. “This recognition by the Everest Group reinforces our commitment to contextualizing GenAI for some of the most challenging use cases, and help leaders tackle them with fit-for-purpose solutions.”
Everest Group assessed each service provider’s GenAI capabilities on 4 specific parameters: scale, with a focus on revenue, client reach and pipeline; the quality and impact of industry-specific use cases across the value chain either in pilot or production stages; the kind of strategic partnerships across the board and the capability boost thereof; and the quantum of real, measurable value realized by clients.
To download the full report, click here.
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. Its client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. Indegene has over 5,000 employees worldwide, 6 operation hubs and 18 offices across North America, Europe, and Asia.
About Indegene
Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives Indegene’s team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com
